Prioritizing Benefit? How Low-Income Patients Respond to Prescription Cost Sharing
Medicare-Medicaid patients are automatically enrolled in the federal Low-Income Subsidy, which keeps their medication copayments very low. Those who lose Medicaid coverage before August may lose this subsidy in the following January, whereas those who lose Medicaid in August or later typically retain the subsidy for an additional year. In “Prioritizing Benefit? How Low-Income Patients Respond to Prescription Cost Sharing,” Chris Hollrah uses these distinctions in timing to compare similar people who have—or have not yet—lost this benefit. Doing so, he examines the consequences of a substantial rise in prescription drug cost sharing for low-income Medicare beneficiaries.
When patients who lose the subsidy face higher costs, Dr. Hollrah finds a 40% decrease in overall prescription drug spending. He also finds they fill 16% fewer prescriptions and are more likely to forgo higher-priced medications irrespective of their clinical benefit. In fact, use of high-value medications—including insulin—declines markedly, and the analysis offers suggestive evidence that mortality rises among diabetic patients. Additionally, these cutbacks do not seem to come from using cheaper, generic options as a substitute for expensive drugs.
Overall, Dr. Hollrah finds that increased cost sharing primarily restricts access to necessary treatment rather than steering patients toward more efficient medication choices or eliminating low-value care. To improve efficiency, policies should emphasize value-based drug pricing and provider decision-making, rather than increasing out-of-pocket costs for low-income patients.
On November 12, the AEA recognized one of the paper’s figures in its Featured Charts series. The full paper is accessible here (subscription required).
- Economist